| Autor: |
Levavi H; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York., Hoffman R; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Marcellino BK; Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2022 Jul; Vol. 20 (7), pp. 456-467. |
| Abstrakt: |
Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary hematopoiesis, splenomegaly, and debilitating constitutional symptoms. The advent of JAK inhibitors has changed the landscape of treatment options for patients with MF, providing relatively tolerable drug options that control symptoms, reduce splenomegaly, and improve quality of life, but often at the expense of worsening cytopenias. JAK inhibitors do not appear to halt the progression of disease or prevent leukemic transformation, and their effect on survival is debated. Here, we review both the US Food and Drug Administration-approved JAK inhibitors and those in late-phase clinical trials, with a focus on clinical activity and unique adverse effects. We also provide a schema for choosing among these options for patients with MF. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
